ARNA Stock - Arena Pharmaceuticals, Inc.
Unlock GoAI Insights for ARNA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Revenue | $54,000 | $319,000 | $806.43M | $17.97M | $21.34M |
| Gross Profit | $54,000 | $319,000 | $806.43M | $17.97M | $21.34M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-612,274,000 | $-426,639,000 | $482.75M | $-144,783,000 | $-91,967,000 |
| Net Income | $-620,592,000 | $-404,734,000 | $397.56M | $-29,399,000 | $-91,407,000 |
| Net Margin | -1149244.4% | -126875.9% | 49.3% | -163.6% | -428.4% |
| EPS | $-11.33 | $-7.39 | $7.69 | $-0.62 | $-2.77 |
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.
Visit WebsiteEarnings History & Surprises
ARNAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2022 | May 4, 2022 | $-2.32 | — | — | — |
Q1 2022 | Feb 23, 2022 | $-2.26 | $-2.39 | -5.8% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-2.53 | $-3.21 | -26.9% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-2.20 | $-2.40 | -9.1% | ✗ MISS |
Q2 2021 | May 5, 2021 | $-2.16 | $-1.98 | +8.3% | ✓ BEAT |
Q1 2021 | Feb 23, 2021 | $-1.85 | $-2.10 | -13.5% | ✗ MISS |
Q4 2020 | Nov 9, 2020 | $-1.87 | $-1.69 | +9.6% | ✓ BEAT |
Q3 2020 | Aug 5, 2020 | $-2.03 | $-1.61 | +20.7% | ✓ BEAT |
Q2 2020 | May 7, 2020 | $-2.28 | $-2.00 | +12.3% | ✓ BEAT |
Q1 2020 | Feb 26, 2020 | $-1.55 | $-1.76 | -13.5% | ✗ MISS |
Q4 2019 | Nov 7, 2019 | $-1.32 | $-1.46 | -10.6% | ✗ MISS |
Q3 2019 | Aug 7, 2019 | $-1.08 | $-1.24 | -14.8% | ✗ MISS |
Q2 2019 | May 8, 2019 | $13.89 | $12.10 | -12.9% | ✗ MISS |
Q1 2019 | Feb 26, 2019 | $-0.76 | $1.35 | +277.6% | ✓ BEAT |
Q4 2018 | Nov 7, 2018 | $-0.74 | $-0.70 | +5.4% | ✓ BEAT |
Q3 2018 | Aug 6, 2018 | $-0.64 | $-0.65 | -1.6% | ✗ MISS |
Q2 2018 | May 8, 2018 | $-0.68 | $-0.80 | -17.6% | ✗ MISS |
Q1 2018 | Mar 14, 2018 | $-0.59 | $-0.35 | +40.7% | ✓ BEAT |
Q4 2017 | Nov 7, 2017 | $-0.67 | $-0.86 | -28.4% | ✗ MISS |
Q3 2017 | Aug 7, 2017 | $-0.74 | $-0.77 | -4.1% | ✗ MISS |
Latest News
Frequently Asked Questions about ARNA
What is ARNA's current stock price?
What is the analyst price target for ARNA?
What sector is Arena Pharmaceuticals, Inc. in?
What is ARNA's market cap?
Does ARNA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ARNA for comparison